Teon Therapeutics Names Serge Messerlian as CEO and Announces First Patient Dosed on TT-702
Teon Therapeutics, a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced the appointment of Serge Messerlian as Chief Executive Officer and member of the board of directors. The company also announced the first patient dosed in Phase 1/2 clinical trial of lead asset, TT-702.
Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways, today announced the forthcoming oral presentation of preclinical data on selective adenosine A2B receptor antagonist TT-702, at the American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10-15, 2021.
Cancer Research UK and Teon Therapeutics Advance New First-In-Class Cancer Drug Into Clinical Trial
Cancer Research UK and Teon Therapeutics, Inc. (Teon) today (Monday 1 March) announce that they have signed a collaboration agreement to progress the early phase clinical development of Teon’s first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Teon Therapeutics Completes $30 Million Series A Financing
Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
Teon Therapeutics Appoints Glen Giovannetti as Independent Board Member
Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointment of Glen Giovannetti, to its board of directors. Glen brings over 36 years of leadership success, industry expertise and board governance credentials following his retirement from EY (Ernst & Young) in December 2020.
Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK
Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced that Cancer Research UK, the world’s leading cancer charity dedicated to saving lives, has formally approved Teon’s TT-702 program to enter into a clinical collaboration.
Teon Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020
Teon Therapeutics, Inc. has been invited to present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020. Teon is scheduled to present on October 15 at 11:40am PT, with one-on-one meetings to be held throughout the conference.
Teon Therapeutics Appoints Biotech Veteran Louis Lange as Independent Board Member
Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointed of Louis Lange, MD, PhD, to its board of directors. Dr. Lange is a renowned academic Chief of Cardiology and biotech veteran, having founded CV Therapeutics in 1992 and served as its Chairman, CEO and CSO.
Teon Therapeutics Appoints Ken Horne as President & Chief Operating Officer
Teon Therapeutics, a pharmaceutical company developing novel small molecules focused on GPCR targets for oncology indications, today announced the appointment of Ken Horne as President and Chief Operating Officer. With this appointment, Mr. Horne will take responsibility for operations, business development and fund raising for Teon Therapeutics.